Menopause
Vaginal estrogen not tied to recurrence risk in younger endometrial cancer survivors
A large propensity‑matched cohort study using the TriNetX US Collaborative Network evaluated vaginal estrogen therapy (ET) in endometrial cancer survivors aged 18 to 51. Despite more than 23,000 eligible survivors, only 5.6% initiated vaginal ET, highlighting substantial underutilization. Among 1,412 ET users matched 1:1 with 1,412 non‑users, short‑term vaginal ET (mean duration, 1.88 years) wasn’t associated with an increased risk of cancer recurrence (hazard ratio, 0.87; 95% confidence interval, 0.60–1.27).
Clinical takeaway: Consider local, low‑dose vaginal estrogen as a safe option for managing genitourinary symptoms in younger endometrial cancer survivors who are appropriate candidates.
Source:
Hsu CD, et al. (2026, March 3). Menopause. Vaginal estrogen therapy utilization and associated outcomes in younger survivors of endometrial cancer. https://pubmed.ncbi.nlm.nih.gov/41774009/